Frontline therapy of CLL: where do we stand? – Wednesday, October 1, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content Frontline therapy of CLL: where do we stand? – Wednesday, October 1, 2025 Read More »
JOURNAL CLUB – Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE – Monday, February 10, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content JOURNAL CLUB – Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE – Monday, February 10, 2025 Read More »
CLL Academy – Highlights of CLL Data Presented at the ASH 2025 – Tuesday, December 16, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content CLL Academy – Highlights of CLL Data Presented at the ASH 2025 – Tuesday, December 16, 2025 Read More »
CLL Academy – IACH Journal Club – Zanubrutinib and Venetoclax for Patients With Treatment-Na¨ ıve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results – Tuesday, July 8, 2025 Uncategorized / Sharon Rawet Lederer Open to access this content CLL Academy – IACH Journal Club – Zanubrutinib and Venetoclax for Patients With Treatment-Na¨ ıve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results – Tuesday, July 8, 2025 Read More »
